Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Screening Platform

By Drug Discovery Trends Editor | June 23, 2010

Scil Proteins, a private biotech company specialized in the discovery, development and production of recombinant proteins, announced that it has achieved validation of its proprietary Affilin drug discovery platform in animals. The Company’s lead product, SPVF 2801, an Affilin molecule for applications in solid tumors passed initial preclinical studies with excellent results.

Affilin molecules are scaffold proteins derived from the natural serum protein ubiquitin. They bind disease related targets with high affinity and specificity. Scil Proteins’ platform combines proprietary Affilin® libraries with Ribosome and Tat Phage Display screening technologies, allowing fast identification of Affilin therapeutics. The power of this technology has been demonstrated by the fact that it took only five months from the start of candidate selection to move the lead candidate into the first preclinical animal study.

Scil Proteins’ lead program aims at the development of Affilin® molecules for a clinically validated cancer target. The validation was achieved showing an accumulation of SPVF 2801 in solid tumors in a mouse model, indicating that the picomolar binder targets the tumor cells with high specificity in vivo. Based on these results, Scil Proteins will continue pre-clinical development within its cancer lead program and will also progress with screening its Affilin libraries for candidates against additional targets.

The discovery platform uses an accelerated screening process that made use of advanced library design and high-quality ubiquitin libraries with a complexity of 1017. Scil Proteins has complete freedom to operate with these therapeutic Affilin® molecules. The clinically validated solid tumor target used in the screening offers a very broad range of applications in cancer therapy.

“Our goal has been to establish a robust and fast screening platform for the identification of targeted therapeutics. We are therefore extremely pleased with the outcome of this animal study. The high affinity and specificity of the Affilin® candidate seen in biochemical as well as cell culture assay translated nicely into a specific accumulation within the tumor. We are currently working on several other targets,” commented Dr. Arnd Steuernagel, CSO.

“Using our accelerated screening process, it took Scil Proteins only five months to achieve in vivo data following primary screening. This clearly demonstrates how powerful our Affilin platform technology is. Our results further endorse and strengthen our integrated business concept to combine innovative drug discovery, process development and GMP manufacturing,” added Dr. Ulrike Fiedler, CEO of Scil Proteins.

Scil Proteins 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50